Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948751 · ClinicalTrials.gov registry record
Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 14
- Enrollment target
NCT02948751 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 14 participants.
The verdict
NCT02948751 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This study will prospectively enroll 36 evaluable subjects with breast cancer who are undergoing workup for clinical suspicion of leptomeningeal metastasis (LM). Neuroimaging consisting of MRI of the brain or total spine (or both, as clinically indicated) will be obtained in all patients. Patients will also undergo a lumbar puncture and standard CSF evaluation, which may consist of intracranial pressure measurement, CSF protein, glucose, white and red cell analysis, infectious cultures, as well as conventional cytopathologic analysis (cytocentrifuge). An additional CSF sample will be obtained for evaluation of CSF CTCs by OncoCEETM technology and cell-free DNA (recommended amount: 1 tube, 10 mL) at the time of lumbar puncture.
Interventions
- DEVICE OncoCEE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2019-12-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02948751
The ClinicalTrials.gov registry entry for NCT02948751 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OncoCEE is the first listed.
NCT02948751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02948751 about?
NCT02948751 is a clinical study titled "Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer". This study will prospectively enroll 36 evaluable subjects with breast cancer who are undergoing workup for clinical suspicion of leptomeningeal metastasis (LM). Neuroimaging consisting of MRI of the brain or total spine (or both, as clinically indicated) will be obtained in all patients. Patients w...
What is the current status of trial NCT02948751?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2017-02-06. Estimated completion is 2019-12-18.
What interventions are being tested in trial NCT02948751?
The interventions under investigation include: OncoCEE (DEVICE).
Who is sponsoring clinical trial NCT02948751?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.